To hear about similar clinical trials, please enter your email below
Trial Title:
Role of 18F-FDG PET/CT in Gastric Cancer
NCT ID:
NCT05687552
Condition:
Gastric Cancer
Conditions: Official terms:
Stomach Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Device
Intervention name:
pet -ct
Description:
assessment of added value of pet -ct in patients with gastric cancer and how patient get
benefit from this finding
Summary:
The objective of the study is to assess the value of PET/CT in diagnosis, staging,
response evaluation, and relapse monitoring of gastric cancer.
Detailed description:
gastric cancer (GC) is the fifth most common malignancy and the third leading cause of
cancer mortality worldwide (1) It carries a poor prognosis, with a 5-year survival of
only 20%-30% (2) Clinical staging, based mainly on imaging, is critical in determining
the best treatment.There is a widely accepted consensus of the usefulness of FDG PET/CT
in staging and restaging of gastric cancer. According to evidence-based data, this
modality can evaluate gastric cancer more accurately and is helpful for evaluation of
tumor biologic characteristics, detection of lymph node and distant metastases,
assessment of tumor response to therapy(9).
retrospective and prospective study will conducted at Sohag oncology hospital, nuclear
medicine unit& Assuit university hospital, nuclear medicine unit including 50 patients in
12 months .
Criteria for eligibility:
Study pop:
patient diagnosed by pathology as gastric cancer
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. patients diagnosed as GC on surgically resected specimens;
2. Patients with gastric and extragastric metastasis.
3. patients with gastric cancer either operated or not.
Exclusion Criteria:
1. Patients with second malignancy.
2. Patient without proven pathology of cancer stomach.
3. Severely ill patient (patient with disturbed conscious level, or couldn't lay supine
during the imaging).
4. uncontrolled diabetic patient with blood glucose level more than 200mg\dl.
5. pregnant women
Gender:
All
Minimum age:
18 Years
Maximum age:
70 Years
Start date:
January 2023
Completion date:
January 2024
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05687552
